RD
Therapeutic Areas
Nanexa Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NEX-22 | Type 2 Diabetes / Obesity (Liraglutide) | Phase I |
| NEX-20 | Oncology (Undisclosed) | Preclinical |
| NEX-18 | Oncology (Undisclosed) | Preclinical |
| Moderna Collaboration | Undisclosed | Discovery |
| AstraZeneca Collaboration | Undisclosed | Research |
| Novo Nordisk Collaboration | Undisclosed | Research |
Leadership Team at Nanexa
DW
David Westberg
Chief Executive Officer
CD
Cecilia Danckwardt-Lillieström
Chief Financial Officer
MR
Mårten Rooth
Chief Technology Officer, Co-founder
JH
Joel Hellrup
Head of Pharmaceutical R&D
KB
Kristine Bäck
Director Project Management
AJ
Anders Johansson
Head of Intellectual Property, Co-founder
GA
Göran Ando
Chairman of the Board
BS
Birgit Stattin Norinder
Board Member
JD
Jakob Dynnes Hansen
Board Member